Magna Concursos

Foram encontradas 160 questões.

4257822 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
Read the sentences and evaluate the meanings and grammatical uses of the highlighted phrasal verbs.
(   ) In "The research team carried out several interviews," carried out means conducted.
(   ) In "The school turned down the proposal," the object pronoun may be correctly placed as in "The school turned it down."
(   ) In "The volunteer looked after the children," the phrasal verb is separable and may be rewritten as "The volunteer looked the children after."
(   ) In "She eventually got over the disappointment," got over means examined the disappointment carefully.
Mark T for true statements and F for false statements. Then select the alternative that presents the CORRECT sequence
 

Provas

Questão presente nas seguintes provas
4257821 Ano: 2026
Disciplina: Pedagogia
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
A public school organizes an English-language information project about access to municipal services. Students analyse forms and websites, identify barriers to comprehension and produce plain-language guides for different audiences. Which assessment design most coherently reflects the formative and civic dimensions of the project?
 

Provas

Questão presente nas seguintes provas
4257820 Ano: 2026
Disciplina: Pedagogia
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
During a lesson on requesting information, students first listen to a short exchange at a train station. They identify expressions used to ask about departure times, adapt the dialogue to new destinations, and perform similar interactions with different classmates. The teacher provides brief feedback on clarity and appropriateness. The lesson is most consistent with:
 

Provas

Questão presente nas seguintes provas
4257819 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
Four students must produce a podcast in English. One member misses deadlines, another begins making decisions without consultation, and the remaining students avoid discussing the conflict. The teacher decides to structure a group review meeting. Which sequence best promotes assertive communication and shared responsibility?
 

Provas

Questão presente nas seguintes provas
4257818 Ano: 2026
Disciplina: Pedagogia
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
An English teacher organizes a unit in which students compare posts, news reports and public-service messages about the same environmental issue. They examine audience, purpose, vocabulary and source credibility before creating a bilingual awareness campaign for the school community. The activity most appropriately treats English as:
 

Provas

Questão presente nas seguintes provas
4257817 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
The article presents Lilly's acquisition of AtaiBeckley as part of a broader corporate strategy. Based on the information provided, the acquisition may be interpreted as an attempt to:
 

Provas

Questão presente nas seguintes provas
4257816 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher uses the article to discuss how pharmaceutical research, regulation, investment and public communication interact across national borders. The teacher wants to avoid turning the lesson into either commercial promotion or an unsupported debate about medical treatment. Register T for true statements and F for false statements.
(   ) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
(   ) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
(   ) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
(   ) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
 

Provas

Questão presente nas seguintes provas
4257815 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
Read the excerpt:
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
 

Provas

Questão presente nas seguintes provas
4257814 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher prepares an audio adaptation of the article and asks students to identify the difference between confirmed information and market projections. Before listening, the teacher provides the categories confirmed transaction, clinical expectation, and financial estimate. Which procedure most effectively develops the intended listening skill?
 

Provas

Questão presente nas seguintes provas
4257813 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
After reading the article, students compare the headline, financial projections, quoted analysts and descriptions of clinical development. They then produce a short English-language briefing distinguishing facts, forecasts and corporate interests.
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
 

Provas

Questão presente nas seguintes provas